Carcinogenesis, cancer therapy and chemoprevention

被引：81
作者：
Blagosklonny, MV [1 ]
机构：
[1] New York Med Coll, Brander Canc Res Inst, Hawthorne, NY 10532 USA
来源：
CELL DEATH AND DIFFERENTIATION | 2005年 / 12卷 / 06期
关键词：
carcinogenesis; cancer therapy; chemoprevention;
D O I：
10.1038/sj.cdd.4401610
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Carcinogenesis and cancer therapy are two sides of the same coin, such that the same cytotoxic agent can cause cancer and be used to treat cancer. This review links carcinogenesis, chemoprevention and cancer therapy in one process driven by cytotoxic agents (carcinoagents) that select either for or against cells with oncogenic alterations. By unifying therapy and cancer promotion and by distinguishing nononcogenic and oncogenic mechanisms of resistance, I discuss anticancer- and chemopreventive agent-induced carcinogenesis and tumor progression and, vice versa, carcinogens as anticancer drugs, anticancer drugs as chemopreventive agents and exploiting oncogene-addiction and drug resistance for chemoprevention and cancer therapy.
引用
收藏
页码：592 / 602
页数：11
相关论文
共 155 条
[1]  
Altieri DC, 2004, CELL CYCLE, V3, P255
[2]   Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death [J].
Amarante-Mendes, GP ;
Finucane, DM ;
Martin, SJ ;
Cotter, TG ;
Salvesen, GS ;
Green, DR .
CELL DEATH AND DIFFERENTIATION, 1998, 5 (04) :298-306
[3]   Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia [J].
Barnes, DJ ;
Melo, JV .
ACTA HAEMATOLOGICA, 2002, 108 (04) :180-202
[4]   Neoplastic and antineoplastic effects of β-carotene on colorectal adenoma recurrence:: Results of a randomized trial [J].
Baron, JA ;
Cole, BF ;
Mott, L ;
Haile, R ;
Grau, M ;
Church, TR ;
Beck, GJ ;
Greenberg, ER .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (10) :717-722
[5]   Treating cancer's kinase 'addiction' [J].
Baselga, J ;
Arribas, J .
NATURE MEDICINE, 2004, 10 (08) :786-787
[6]   Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment [J].
Baskaynak, G ;
Kreuzer, KA ;
Schwarz, M ;
Zuber, J ;
Audring, H ;
Riess, H ;
Dörken, B ;
le Coutre, P .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (04) :231-234
[7]   DNA repair protein MGMT protects against N-methyl-N-nitrosourea-induced conversion of benign into malignant tumors [J].
Becker, K ;
Gregel, C ;
Fricke, C ;
Komitowski, D ;
Dosch, J ;
Kaina, B .
CARCINOGENESIS, 2003, 24 (03) :541-546
[8]  
BENEDICT WF, 1977, CANCER RES, V37, P2202
[9]   Second cancers in survivors of childhood cancer [J].
Bhatia, S ;
Sklar, C .
NATURE REVIEWS CANCER, 2002, 2 (02) :124-+
[10]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
12345678910